Physician profile
Carl Barsigian
NPI 1871582569
$4,793.91
in general payments reported to CMS, 2019-2025
47 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $14.95 · 2021: $357 · 2022: $239 · 2023: $1,103 · 2024: $1,098 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.16 |
| Education | $173.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $851.78 | 2019-2025 | Calquence, Datroway, Imfinzi |
| Beigene USA, INC. | $587.87 | 2021-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $307.41 | 2019-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $304.23 | 2019-2025 | |
| Celgene Corporation | $294.48 | 2019-2023 | Pomalyst |
| Genentech USA, INC. | $193.01 | 2019-2025 | Tecentriq, Rozlytrek, Alecensa |
| Glaxosmithkline, LLC. | $181.58 | 2021-2024 | Ojjaara |
| Beone Medicines USA, INC. | $172.06 | 2025 | Brukinsa |
| Pfizer INC. | $168.10 | 2019-2025 | |
| Sobi, INC | $149.07 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $121.35 | 2019-2025 | |
| Janssen Biotech, INC. | $114.17 | 2019-2025 | Erleada, Talvey, Darzalex |
| Cti Biopharma Corp. | $112.52 | 2023 | Vonjo |
| Daiichi Sankyo INC. | $96.81 | 2019-2025 | Enhertu |
| Astellas Pharma US INC | $78.13 | 2019-2024 | Padcev, Xtandi |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.72 | 2019-2023 | Keytruda |
| Exelixis INC. | $61.81 | 2019-2025 | Cabometyx |
| Eisai INC. | $61.42 | 2019-2024 | |
| Lilly USA, LLC | $59.07 | 2019-2023 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $58.94 | 2019-2025 | Fruzaqla |
| Incyte Corporation | $56.83 | 2022-2025 | Monjuvi, Jakafi |
| Abbvie INC. | $55.86 | 2019-2024 | |
| Genzyme Corporation | $53.45 | 2019-2023 | |
| Rigel Pharmaceuticals, INC. | $50.01 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Karyopharm Therapeutics INC. | $48.78 | 2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $45.47 | 2019-2023 | Ultomiris |
| Array Biopharma INC | $45.15 | 2019-2025 | Braftovi, Mektovi |
| Gilead Sciences, INC. | $35.25 | 2021-2024 | |
| Pharmaessentia USA Corporation | $34.24 | 2023-2025 | Besremi |
| Seagen INC. | $28.73 | 2019-2023 | Adcetris |
| Accord Healthcare, INC. | $26.47 | 2025 | |
| Tersera Therapeutics LLC | $23.32 | 2024 | Zoladex |
| Pharmacosmos Therapeutics INC. | $22.50 | 2025 | Monoferric |
| Adaptive Biotechnologies Corporation | $21.66 | 2023 | Clonoseq |
| Amgen INC. | $18.93 | 2024 | Kyprolis, Neulasta, Vectibix |
| Caris Mpi, INC. | $17.86 | 2025 | Mi Cancer Seek |
| Geron Corporation | $17.79 | 2025 | Rytelo |
| Immunocore Limited | $17.20 | 2025 | Kimmtrak |
| Myriad Genetic Laboratories, INC. | $16.31 | 2023 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $15.94 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.55 | 2019 | |
| Puma Biotechnology, INC. | $15.19 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.35 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.04 | 2019 | |
| Clovis Oncology, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Barsigian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.